Get started
Author

Timothy J. Panella

High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine
1992 · D. L. Trump, D. C. Smith, et al. · JNCI Journal of the National Cancer Institute · 207
Prognostic Value of Breast Cancer Subtypes, Ki-67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian Women
2012 · N. Lynn Ferguson, John Bell, et al. · The Breast Journal · 87
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells
1991 · R E Dornsife, M H St Clair, et al. · Antimicrobial Agents and Chemotherapy · 80
Is the TNM Staging System for Breast Cancer Still Relevant in the Era of Biomarkers and Emerging Personalized Medicine for Breast Cancer - An Institution's 10-year Experience
2015 · Amila Orucevic, Jason Chen, et al. · The Breast Journal · 41
PDF
Platelets acquire a secretion defect after high-dose chemotherapy
1990 · Timothy J. Panella, William Peters, et al. · Cancer · 30
PDF
A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
2011 · Adam Brufsky, Karen Hoelzer, et al. · Clinical Breast Cancer · 29
Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer
1998 · Markus F. Renschler, Alan R. Yuen, et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · 29
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060
1996 · Elizabeth A. Poplin, Joth Jacobson, et al. · Cancer · 26
PDF
Relationship Between Response Rate and Median Survival in Patients With Advanced Nonsmall Cell Lung-cancer - Comparison of Onconase(r) With Other Anticancer Agents
1995 · SM MIKULSKI, HG CHUN, et al. · International Journal of Oncology · 26
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
1992 · T J Panella, D C Smith, et al. · PubMed · 24
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study
1995 · Stephen K. Williamson, John J. Crowley, et al. · Investigational New Drugs · 20
A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
2016 · Carlos Becerra, Fadi S. Braiteh, et al. · Journal of Clinical Oncology · 13
Oral microbiome and mycobiome dynamics in cancer therapy-induced oral mucositis
2025 · Laurentia Nodit, Joseph R. Kelley, et al. · Scientific Data · 8
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
2024 · Oleksandr Dudnichenko, Konstantin Penkov, et al. · European Journal of Cancer · 8
PDF
Breast Cancer in Elderly Caucasian Women—An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall Survival
2015 · Amila Orucevic, Matthew Curzon, et al. · Cancers · 8
PDF
Metastasis of squamous cell carcinoma of the bladder to the heart: Case report and review of the literature
2006 · Wesley M. White, W. Bedford Waters, et al. · Urology · 7
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
2023 · Timothy J. Panella, Sajeve Samuel Thomas, et al. · Journal of Clinical Oncology · 6
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
2023 · Diwakar Davar, Alexandra Ikeguchi, et al. · Journal of Clinical Oncology · 5
PDF
A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.
2017 · William Jeffery Edenfield, Carlos Becerra, et al. · Journal of Clinical Oncology · 4
Effect of thimerosal in leukemia, in leukemic cell lines, and on normal hematopoiesis.
1990 · T J Panella, A T Huang · PubMed · 4
1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma
2021 · D. Schadendorf, R. Dummer, et al. · Annals of Oncology · 3
PDF
Absence of phosphatidylinositol (PI)‐linked proteins in a very early human multipotential haematopoietic marrow cell
1991 · Andrew T. Huang, Timothy J. Panella, et al. · British Journal of Haematology · 3
CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting.
2025 · Soo J. Park, Guilherme Rabinowits, et al. · Journal of Clinical Oncology · 2
349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
2020 · Alain Algazi, William Smith, et al. · Regular and Young Investigator Award Abstracts · 2
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
2023 · Dirk Schadendorf, Reinhard Dummer, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 32
Citation count: 675
H-index: 12
I10-index: 12
Year
Topic
Type